LE WE PMID CA
Bevacizumab ttVEGF4315Bevacizumab ttVEGF

81C6 ttTenascin

Abatacept ttCTLA4Conjugate

Abciximab ttGPIIAIIIB

Adalimumab ttTNFalpha

AIN457

Alemtuzumab ttCD52

AMG386 ttAngiopoietin1 ttAngiopoietin2

Antibodies (therapeutic use)

Atacicept ttBlys ttAPRIL

Bapineuzumab ttAmyloidBeta

Basiliximab ttIL2R

Belatacept ttCD80 ttCD86

Belimumab ttBLyS

Bevacizumab ttVEGF

Brentuximab vedotin ttCD30

Briakinumab ttIL12 ttIL23

Canakinumab ttIL1beta

Catumaxomab ttEpCAM ttCD3 linkerAb

Certolizumab ttTNFalpha

Cetuximab ttEGFR

CNS (Neoplasia Glioblastoma)

CNS (Neoplasia Glioma)

Colon and rectum (Neoplasia)

Daclizumab ttIL2R

Dalotuzumab ttIGF1R

Denosumab ttRANKL

Eculizumab ttFactorH

Efalizumab ttLFA1

Epratuzumab ttCD22

Etanercept ttTNFalpha

Everolimus

Eye (Pharmacology)

FactorIXFc ttFactorIX

FactorVIIIFc ttFactorVIII

Farletuzumab ttFolateRalpha

Figitumumab ttIGF1R

Galiximab ttCD80

Gemtuzumab ozogamicin ttCD33

Girentuximab ttCarbonicAnhydraseIX

Golimumab ttTNFalpha

Heart (Takotsubo s syndrome)

Ibritumomab tiuxentan yttrium ttCD20

Infliximab ttTNFalpha

Inotuzumab ozogamicin ttCD22

Ipilimumab ttCTLA4

Kidney (Neoplasm)

Mepolizumab ttIL5

Motavizumab ttRSVirus

MuromonabCD3 ttCD3

Naptumomab estafenatox tt5T4

Natalizumab ttIntegrinalpha4

Necitumumab ttEGFR

Nimotuzumab ttEGFR

Obinutuzumab ttCD20

Ocrelizumab ttCD20

Ofatumumab ttCD20

Omalizumab ttCD20

Otelixizumab ttCD3

Pagibaximab ttLipoteichoicAcidStaphlococcus

Palivizumab ttRSVirusFprotein

Panitumomab ttEGFR

Pazopanib

Pegaptanib

Pertuzumab ttHER2

Ramucirumab ttVEGFR2

Ranibizumab ttVEGF

Raxibacumab ttAnthrax

REGN88 ttIL6R

Reslizumab ttIL5

Rilonacept ttIL1R

Rituximab ttCD20

Solanezumab ttAmyloidBeta

Sorafenib

Sunitinib

T1H ttCD6

Tanezumab ttNGF

Temsirolimus

Teplizumab ttCD3

Tocilizumab ttIL6

Tositumomab ttCD20

Trastuzumab emtansine ttHER2

Trastuzumab ttHER2

Tremelimumab ttCLTA4

Ustekinumab ttIL12 ttIL23

Vedolizumab ttIntegrina4b7

Zalutumumab ttEGFR

Zanulimumab ttCD4

2008  
1
Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer.
[19337443] Ther Clin Risk Manag 4(6): 1367-70 (2008)
2010  
2
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
[20028613] Health Technol Assess 14(2): 1-184, iii-iv (2010)
2007  
3
Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
[17346499] Health Technol Assess 11(12): 1-128, iii-iv (2007)
2004  
4
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.
[15886877] Angiogenesis 7(4): 335-45 (2004)
2005  
5
Bevacizumab--current status and future directions.
[15939715] Ann Oncol 16(7): 999-1004 (2005)
2007  
6
A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
[17951900] Indian J Ophthalmol 55(6): 437-9 (2007)
2007  
7
Bevacizumab: off-label use in ophthalmology.
[17951896] Indian J Ophthalmol 55(6): 417-20 (2007)
2010  
8
Targeted therapy for renal cell cancer: current perspectives.
[21122471] Discov Med 10(54): 394-405 (2010)
2007  
9
Vascular endothelial growth factor: biology and therapeutic applications.
[17537667] Int J Biochem Cell Biol 39(7-8): 1349-57 (2007)
2010  
10
2009  
11
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
[19897538] Oncologist 14(11): 1131-8 (2009)
2007  
12
Intravitreal bevacizumab: an analysis of the evidence.
[19668481] Clin Ophthalmol 1(3): 273-84 (2007)
2010  
13
Bevacizumab for malignant gliomas.
[20212225] Arch Neurol 67(3): 285-8 (2010)
2011  
14
Antibody-based therapeutics to watch in 2011.
[21051951] MAbs 3(1): 76-99 (2011)
2010  
15
Therapeutic antibodies in ophthalmology: old is new again.
[21358858] MAbs 2(2): 176-80 (2010)
2010  
16
Antibodies to watch in 2010.
[20065640] MAbs 2(1): 84-100 (2010)
2011  
17
Bevacizumab for the treatment of recurrent glioblastoma.
[21603247] Clin Med Insights Oncol 5(-): 117-29 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Bevacizumab ttVEGF

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia